ArticleJHLT open2026
Robotic-assisted lung decortication in the management of pleural space complications after lung transplant.
Article in JHLT open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Robotic-assisted decortication has not been reported in post-lung transplant patients. We reviewed 26 consecutive robotic decortication for lung entrapment syndrome from 2019 to 2024. The time from transplant to decortication was 516 days (IQR 260-887). No thoracotomy conversion was necessary. Median chest tube duration was 4 days (IQR 3-6.5), and median length of stay was 6 days (IQR 3-7). Eighty-eight percent of cases achieved complete lung expansion with a median 315 ml improvement in FVC and 235 ml improvement in FEV1. The most severe Clavien-Dindo complications included 1 take-back for airleak and 1 re-intubation. Robotic-assisted decortication was well tolerated, safe, and effective at removing the fibrotic pleural disease and reversing previously defunctionalized lung.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.